In this randomised , open-label , phase @ study , adult patients with platinum-sensitive , recurrent , high-grade serous ovarian cancer who had received up to three previous courses of platinum-based chemotherapy and who were progression free for at least @ months before randomisation received either olaparib ( @ mg capsules twice daily , administered orally on days @-@ of each @-day cycle ) plus paclitaxel ( @ mg/m ( @ ) , administered intravenously on day @ ) and carboplatin ( area under the curve -LSB- AUC -RSB- @ mg/mL per min , according to the Calvert formula , administered intravenously on day @ ) , then olaparib monotherapy ( @ mg capsules twice daily , given continuously ) until progression ( the olaparib plus chemotherapy group ) , or paclitaxel ( @ mg/m ( @ ) on day @ ) and carboplatin ( AUC @ mg/mL per min on day @ ) then no further treatment ( the chemotherapy alone group ) .